Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients.

Autor: Eikenes G; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary., Liszkay G; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary.; National Tumor Laboratory Project, H1122 Budapest, Hungary., Balatoni T; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary., Czirbesz K; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary.; National Tumor Laboratory Project, H1122 Budapest, Hungary., Hunyadi K; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary., Kozéki Z; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary., Kispál MT; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary.; National Tumor Laboratory Project, H1122 Budapest, Hungary., Baranyai F; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary., Danyi T; Department of Dermato-Oncology, National Institute of Oncology, H1122 Budapest, Hungary., Bőcs K; Department of Diagnostic Radiology, National Institute of Oncology, H1122 Budapest, Hungary., Kenessey I; National Tumor Laboratory Project, H1122 Budapest, Hungary.; National Cancer Registry, National Institute of Oncology, H1122 Budapest, Hungary.; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H1091 Budapest, Hungary.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Aug 04; Vol. 15 (15). Date of Electronic Publication: 2023 Aug 04.
DOI: 10.3390/cancers15153966
Abstrakt: Background: The introduction of immuno- and targeted therapeutic modalities meant a breakthrough step in the therapy of melanoma. As a checkpoint inhibitor, the more effective and less toxic anti-PD1 therapy followed an anti-CTLA4 approach.
Methods: From our patient pool, 222 advanced melanoma cases were selected, where anti-PD1 (pembrolizumab, nivolumab) therapy was initiated between March 2015 and December 2020. During our retrospective analysis, the efficacy and safety of the therapy were assessed.
Results: The median follow-up was 16 months (interval: 0-64 months), and 150 patients (67.6%) received therapy in the first line, while second and third line therapy was performed among 72 patients (32.4%) for the median of 7.0 months (0-60). In 50 cases, BRAF mutations were detected. Ninety-six patients showed objective response (11.3% CR, 32.0% PR). The median PFS was 10.0 months (0-60), and the median OS was 23.0 months (0-64). Autoimmune side effects were found in 79 patients (35.5%); grade 3 occurred in 6.3% of the cases, while 1 patient died due to fulminant pneumonitis (0.25%).
Conclusion: Although the range of immunotherapeutic options is getting wider, in the management of melanoma patients, anti-PD1 monotherapy remains an important, effective, and safe method. However, significant correlation was found between the immune-related side effects and therapeutic efficacy.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje